Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Institute for Neurodegenerative Disorders Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC

NCT01268020
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F]-FMH3
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 2, 2026, 2:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients

NCT00096876
View directory record Official record
Conditions
Parkinson Disease, Parkinsonian Syndrome
Interventions
Not listed
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 2, 2026, 2:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

NCT04477785
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
30 Years and older
Enrollment
4,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2033
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 2, 2026, 2:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

NCT01767493
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
[18F]Florbetapir PET imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 2, 2026, 2:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects

NCT00612872
View directory record Official record
Conditions
Parkinson Disease, Alzheimer Disease, Healthy Controls, Multiple Sclerosis
Interventions
[123I]CLINDE
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 2, 2026, 2:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease

NCT00886951
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
I123MNI388/I123MNI390
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 2, 2026, 2:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects

NCT00605046
View directory record Official record
Conditions
Alzheimer Disease
Interventions
SPECT scan
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Oct 2, 2026, 2:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition

NCT00657813
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MNI-330 as a brain SPECT tracer of Beta-Amyloid
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 2, 2026, 2:15 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies

NCT07640555
View directory record Official record
Conditions
Multiple System Atrophy (MSA), Healthy Adult, Parkinson Disease
Interventions
[¹⁸F]MODAG-009 PET imaging
Drug
Lead sponsor
MODAG GmbH
Industry
Eligibility
50 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 2, 2026, 2:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558

NCT01217021
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F] MNI-558
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 2, 2026, 2:15 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease

NCT00387075
View directory record Official record
Conditions
Parkinson Disease
Interventions
[123I]β-CIT and SPECT imaging, [123I]β-CIT
Procedure · Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 2, 2026, 2:15 AM EDT
Completed Phase 2 Interventional

Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease

NCT00397696
View directory record Official record
Conditions
Parkinson Disease
Interventions
[123I] 5-IA
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 2, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease

NCT00117819
View directory record Official record
Conditions
Parkinsonian Syndrome
Interventions
[123I]ß CIT and SPECT imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
22 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 2, 2026, 2:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00870519
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
I-123-MNI-168, 123-I MNI-168
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 2, 2026, 2:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

NCT01028209
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Multiple Sclerosis
Interventions
[18F] PBR06
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 2, 2026, 2:15 AM EDT
Completed No phase listed Observational

The Study of the Impact of Disclosing Imaging Study Information to Trial Participants

NCT00354003
View directory record Official record
Conditions
Parkinsonian Syndrome, Parkinson
Interventions
A series of questionnaires
Behavioral
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 2, 2026, 2:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients

NCT00427674
View directory record Official record
Conditions
Parkinson Disease
Interventions
[123I] mZINT injection and serial dynamic SPECT imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Oct 2, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease

NCT00480701
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease
Interventions
[123I]-IBVM
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 2, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions

NCT00870974
View directory record Official record
Conditions
Parkinson Disease, Huntington Disease, Autistic Spectrum Disorders, Fragile X Syndrome, Alzheimer Disease, Mild Cognitive Impairment
Interventions
[18F]FPEB
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 2, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.

NCT00970229
View directory record Official record
Conditions
Parkinson Disease, Huntington Disease
Interventions
[123I]MNI-420
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 2, 2026, 2:15 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513

NCT01000870
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MNI-513-01
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
55 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Oct 2, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

NCT01209156
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F] PBR111
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 2, 2026, 2:15 AM EDT
Completed Phase 2 Interventional

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease

NCT00096720
View directory record Official record
Conditions
Parkinson Disease, Parkinsonian Syndrome
Interventions
levodopa, Mirapex (pramipexole), [123I]ß-CIT and SPECT imaging
Drug · Procedure
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
Oxnard, California • Englewood, Colorado • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2010 · Synced Oct 2, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00556660
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I] AV-151
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 2, 2026, 2:15 AM EDT